IBSA launches Lubion PFS for private fertility clinics in Ireland

IBSA UK & Ireland has introduced Lubion® PFS (progesterone 25 mg, solution for subcutaneous injection) to the Republic of Ireland, marking its first directly supplied fertility product in the country.

The launch provides Irish IVF clinics with a licensed, supported access route for luteal support in Assisted Reproductive Technology (ART).

Lubion® PFS is designed for women who cannot use or tolerate vaginal progesterone preparations. It offers a ready-to-use formulation delivered via pre-filled syringe for once-daily subcutaneous injection.

The product is the first and only licensed aqueous progesterone for subcutaneous use in Ireland and can be self-administered after professional instruction or delivered by a healthcare professional (HCP).

The licensed availability ensures structured distribution across Irish clinics. Previously, subcutaneous progesterone 25mg was available only via EU parallel-import under European branding (Prolutex and Lubion). Now, prescribers can access Lubion® 25mg PFS as a GMS reimbursable item under the HSE primary care reimbursement service, ensuring consistency of supply and distribution alongside direct medical information and support.

With the launch, IBSA can provide tailored patient materials including leaflets, videos, and injection guidance. Healthcare professionals also have access to information resources and a direct IBSA contact for product or medical inquiries. An educational support website, IBSA Fertility, is available for both clinics and patients.

Melissa Mark, Nurse Manager at Therapie Fertility, Ireland, said, “We have incorporated Lubion® into IVF treatment plans in Ireland for many years and having IBSA’s support now gives us strong reassurance and confidence in its continued supply and availability for our patients. Lubion® provides an essential, convenient progesterone option for women who cannot tolerate vaginal preparations, and its subcutaneous formulation facilitates comfortable administration.”

Access the full article for detailed product insights and clinic guidance.